We are operating a multi-target, multi-customer bioproduction platform, developing therapeutic recombinant proteins and vectoring them in the microalgae cell.
We do not bet on just one molecule, extracted from one specific microalgae, to treat one particular disease.
Through our "technological ensemble" of microalgae cell lines, USP-DSP processes, cGMP manufacturing, galenic pharmacology, we are the first CDMO (Contract Development & Manufacturing Organization) using eukaryotic microalgae cells to produce biopharmaceuticals, vectored for ready-to-formulate active compounds.
We are targeting the therapeutic areas of:
- oncology and infectiology with recombinant immunotoxins and recombinant fusion proteins (new generation AMPs), (Ninkarak® platform)
- vaccinations with thermostable antigenic products (AlgaVax® platform).